Roivant offloads biotech stakes in $3B alliance with Japanese pharma

The deal transfers ownership in five Roivant subsidiaries to Sumitomo Dainippon, along with a stake in Vivek Ramaswamy's parent company. 

By Jonathan Gardner • Sept. 6, 2019

With third pharma deal, IFM's unorthodox approach paying off

An inflammatory disease partnership with Novartis is IFM's second this year with the Swiss pharma and follows a 2017 deal with Bristol-Myers Squibb. 

By Ned Pagliarulo • Sept. 5, 2019

Celltrion taps Lonza to produce some of its Remicade biosimilar

Under the deal, Lonza will make Remsima drug substance at its commercial facility in Singapore to cover European and North American markets.

By Jacob Bell • Sept. 5, 2019

Pharmacquired: Vertex has an appetite for deals. Gene therapy is on the menu

CEO Jeffrey Leiden told BioPharma Dive that one or two gene therapy deals wouldn't be surprising as the biotech builds out what he calls its tool kit of technologies.

By Jacob Bell • Sept. 5, 2019

Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure

Acquiring Semma Therapeutics fulfills CEO Jeffrey Leiden's promise that Vertex would explore "potentially larger" deals than it's done in the past.

By Andrew Dunn • Sept. 3, 2019

Catalent's legacy business outshined by acquisitions

The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business. 

By Jacob Bell • Aug. 29, 2019

Immatics shows Celgene isn't done stocking cell therapy pipeline

As its takeover by Bristol-Myers nears closing, Celgene is committing $75 million to research into T-cell redirecting technology.

By Jonathan Gardner • Aug. 28, 2019

Zogenix buys Modis for $250M, building out rare disease pipeline

Modis Therapeutics, a private California-based biotech, is developing a drug for an ultra-rare neuromuscular disorder with no approved treatments.

By Andrew Dunn • Aug. 26, 2019

Amgen buying Celgene's Otezla in $13B deal

The acquisition, which gives Amgen a complement to its top-seller Enbrel, is the biotech's largest since a 2002 deal to buy Immunex.

By Ned Pagliarulo • Updated Aug. 26, 2019

Meet the protein responsible for nearly $100B in cancer drug deals

Kinase-inhibiting drugs like Vitrakvi, Imbruvica and Rozlytrek were at the heart of 20 M&A deals over the past decade, according to a new SVB Leerink report.

By Jacob Bell • Aug. 16, 2019

Pharming deal shows there's still life in struggling cancer drug class

For $20 million, the Netherlands-based company gets access to leniolisib, a PI3K inhibitor developed by Novartis.

By Jonathan Gardner • Aug. 15, 2019

Bayer buys rest of BlueRock, broadening cell therapy bet

The German pharma will pay $240 million upfront in a deal that values the cell therapy biotech at $1 billion. 

By Kristin Jensen • Aug. 8, 2019

Dupixent brings long-awaited profits to Sanofi, Regeneron partnership

A 12-year antibody collaboration generated three approved drugs but, up until now, has never been profitable on a quarterly basis.

By Jacob Bell • Aug. 6, 2019

Novo buys North Carolina plant from Purdue

Located near Novo's sprawling Clayton site, Purdue's facility gives the buyer capacity to manufacture oral drugs like its experimental version of semaglutide.

By Ned Pagliarulo • Aug. 6, 2019

Takeda board lays out Shire integration goals

The Japan-based big pharma made unusual revelations of sales, profit and cost targets for its executive team as it attempts to digest Shire.

By Jonathan Gardner • Aug. 2, 2019

Vertex expects more, perhaps bigger M&A to come

Long the leading company in cystic fibrosis, Vertex's plans have expanded into new therapeutic areas, spurring greater interest in dealmaking.

By Jacob Bell • Aug. 1, 2019

How Mylan ended as a junior partner in its Pfizer deal

Following a failed deal for Perrigo in 2015, Mylan's fortunes turned south as change came quickly to the generic drug industry.

By Jonathan Gardner • July 30, 2019

Big pharma deals show industry's weak spots

Rather than a sign of strength, mega deals like Bristol-Myers' buy of Celgene hint at the industry's weak spots, with pricing joining a list that includes R&D failures and over-reliance on top sellers. 

By Ned Pagliarulo • July 29, 2019

Mylan's tumble ends with Pfizer rescue

A deal marrying Mylan with Pfizer's off-patent drugs unit will help prop up the struggling generics maker now, but long-term growth remains in question.

By Jonathan Gardner • July 29, 2019

Exact Sciences to expand testing reach with $2.8B Genomic Health deal

The Cologuard maker will add Genomic's breast and prostate cancer tests through the deal, targeting a market worth an estimated $20 billion.

By Maria Rachal • July 29, 2019

Neuroscience M&A is top of mind but a hard pill to swallow

Despite investors' hopes, deals for biotechs like Sarepta, Sage and Neurocrine aren't as likely because of ballooning market values and high clinical risk.

By Jacob Bell • July 29, 2019

MyoKardia cuts all ties to Sanofi

Buying back U.S. royalty rights could look cheap for the biotech if mavacamten turns out to be a blockbuster.

By Jonathan Gardner • July 18, 2019

Gilead, Amgen, J&J most likely to buy Otezla, Wall Street predicts

Analysts argue the inflammation drug, which Bristol-Myers has to unload to meet FTC demands, could go for around $5 billion to $10 billion.

By Jacob Bell • July 18, 2019

AbbVie bets on early immuno-oncology asset

Acquiring the private group Mavupharma brings AbbVie a small-molecule agent that acts on the so-called STING pathway.

By Jonathan Gardner • July 15, 2019

Gilead forges closer ties with Galapagos in $5.1B deal

Eschewing a buyout, Gilead head Daniel O'Day instead opted for a partnership approach in his first major development deal as the biotech's CEO.

By Ned Pagliarulo • Updated July 15, 2019